-
Antengene to Boost T Cell Engager Platform with AI Investment and DeepSeek Deployment
•
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced plans to increase investment in establishing a specialized artificial intelligence (AI) department. The move includes deploying DeepSeek, a Chinese advanced AI model for complex reasoning and natural language processing, to accelerate the development of its T cell engager (TCE) platform with spatial…
-
Deepwise Information Integrates DeepSeek into Medical Data Platform
•
Deepwise Information, a leading artificial intelligence company in the medical field, has fully integrated its big data products with DeepSeek, completing the delivery of the DeepSeek R1 model to a hospital in the southwestern region on February 16. Leveraging the outstanding performance of the DeepSeek R1 model in complex tasks…
-
Pharmaceutical Giants Race to Integrate DeepSeek AI for Efficiency Gains
•
On February 14, China’s stock market saw a significant upsurge in the AI pharmaceuticals sector, with healthcare stocks across the board performing strongly. The rally was particularly driven by AI Pharmaceuticals, medical services, and DRG/DIP segments, with companies like Shanghai Runda Medical Technology Co., Ltd. leading the charge, resulting in…
-
DeepSeek’s AI: Transforming Drug Development and Healthcare in China
•
DeepSeek, a Chinese artificial intelligence company, is poised to make a significant impact on the pharmaceutical industry through its advanced natural language processing (NLP) and large language model (LLM) technologies. The potential applications span multiple dimensions, including data-driven research, clinical decision-making, and resource management. This analysis explores the potential impacts…
